Want to see SG:1B1 full AI Analyst Report?
HC Surgical Specialists Ltd (1B1) AI Stock Analysis
Top Page
HC Surgical Specialists Ltd
(SGX:1B1)
The score is driven primarily by strong financial performance (high profitability, robust and consistent cash generation, and a de-risked balance sheet) and very attractive valuation (low P/E and high dividend yield). These positives are partially offset by weak technicals, with the share price trading below all key moving averages.
HC Surgical Specialists Ltd (1B1) vs. iShares MSCI Singapore ETF (EWS)
- Market Cap
- SGD 52.15M
- Dividend Yield
- 6.12%
- Average Volume (3M)
- 24.53K
- Price to Earnings (P/E)
- 8.0
- Beta (1Y)
- 0.22
- Revenue Growth
- 1.42%
- EPS Growth
- -17.12%
- Country
- Singapore
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
HC Surgical Specialists Ltd Business Overview & Revenue Model
Company Description
HC Surgical Specialists Limited, an investment holding company, primarily delivers a diverse spectrum of medical services across Singapore. Through its network of clinics, the company specializes in endoscopic procedures, such as gastroscopies and co...
How the Company Makes Money
null
HC Surgical Specialists Ltd Financial Statement Overview
Summary
Strong overall fundamentals: very high profitability (gross margins mid-80% range in 2022–2025; net margin ~44% in 2025), consistently positive operating and free cash flow with strong cash conversion (FCF roughly ~0.9–1.0x net income in 2021–2025), and a balance sheet that has de-risked materially with lower leverage and expanding equity. Main risk is uneven revenue/earnings trajectory in 2022–2024 and limited validation of 2026 balance sheet efficiency metrics from the provided ratios.
Income Statement
72PositiveBalance Sheet
82Very PositiveCash Flow
88Very Positive| Breakdown | TTM | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.22M | 19.38M | 19.11M | 18.81M | 19.08M | 19.31M |
| Gross Profit | 8.70M | 6.29M | 16.11M | 15.96M | 16.45M | 16.67M |
| EBITDA | 7.14M | 6.59M | 10.88M | 7.01M | 5.96M | 9.59M |
| Net Income | 8.73M | 6.98M | 8.44M | 3.85M | 2.92M | 6.38M |
Balance Sheet | ||||||
| Total Assets | 28.93M | 32.56M | 27.27M | 27.84M | 31.26M | 30.96M |
| Cash, Cash Equivalents and Short-Term Investments | 6.96M | 8.08M | 5.73M | 8.06M | 10.26M | 6.93M |
| Total Debt | 2.40M | 2.69M | 2.78M | 4.34M | 5.50M | 6.25M |
| Total Liabilities | 6.14M | 11.98M | 6.52M | 13.37M | 19.18M | 19.74M |
| Stockholders Equity | 23.11M | 20.91M | 20.95M | 14.69M | 12.10M | 11.00M |
Cash Flow | ||||||
| Free Cash Flow | 6.85M | 7.71M | 6.75M | 6.23M | 6.51M | 6.83M |
| Operating Cash Flow | 7.33M | 7.80M | 7.23M | 6.30M | 7.22M | 7.05M |
| Investing Cash Flow | 1.53M | 158.00K | -444.00K | 2.84M | -1.72M | -1.99M |
| Financing Cash Flow | -9.11M | -5.28M | -9.05M | -7.97M | -6.24M | -9.12M |
HC Surgical Specialists Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:1B1, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.35, below the 50-day MA of 0.34, and below the 200-day MA of 0.35, indicating a bearish trend. The MACD of 0.00 indicates Positive momentum. The RSI at 42.05 is Neutral, neither overbought nor oversold. The STOCH value of 17.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:1B1.
HC Surgical Specialists Ltd Peers Comparison
Overall Rating
- SG:1B177Outperform
SG:OTX66Neutral
SG:8K757Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SG:1B1 | 77Outperform | SGD 52.29M | 8.04 | 29.03% | 6.12% | 1.42% | -17.12% |
| SG:OTX | 66Neutral | SGD 26.91M | 7.93 | 19.60% | 8.40% | -3.11% | -21.50% |
| SG:8K7 | 57Neutral | SGD 46.79M | 22.06 | 1.27% | ― | 4.69% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SG:1B1 | HC Surgical Specialists Ltd | 0.34 | 0.03 | 7.94% | |
| SG:1J5 | Hyphens Pharma International Ltd. | 0.36 | 0.02 | 4.65% | |
| SG:546 | Medtecs International Corporation Ltd. | 0.10 | -0.02 | -18.40% | |
| SG:8K7 | UG Healthcare Corp. Ltd. | 0.07 | -0.03 | -25.00% | |
| SG:MIJ | Alliance Healthcare Group Ltd. | 0.18 | 0.07 | 62.16% | |
| SG:OTX | Medinex Ltd. | 0.20 | -0.02 | -8.26% |
HC Surgical Specialists Ltd Corporate Events
HC Surgical Specialists Delivers Steady Revenue, Lower FY2026 Profit but Maintains Dividend and Expands Specialist Network
HC Surgical Specialists Limited reported FY2026 revenue of S$19.38 million, up 1.4% year-on-year, while profit attributable to shareholders fell 17.2% to S$6.98 million, largely due to non-operational fair value losses on derivative financial instrum...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 03, 2026